Alder Bio and its yeast-produced antibodies take in $40M

Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.

Cancer-drug biotech Agensys sells to Astellas for $387M — but is it a pig in a poke?

Yet another biotech has succumbed to Big Pharma’s deep-pocketed blandishments. Agensys, a decade-old Santa Monica, Calif., biotech with an early-stage pipeline, just agreed to sell itself to Japan’s Astellas Pharma for $387 million in cash. The company’s shareholders can receive up to another $150 million in milestone payments.

Life sciences briefing: Wednesday, Oct. 31, 2007

Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals

Life sciences briefing: Monday, Oct. 22, 2007

Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical

Life sciences briefing: Monday, Sept. 24, 2007

Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital

Life sciences briefing: Monday, Sept. 10, 2007

Featured companies: BioVascular, Carefx, ClinResearch, Healthcare Management Directions, NanoCor, OxyPlus, Revitus, Spotlight Surgical, United BioSource